213 related articles for article (PubMed ID: 22329578)
1. Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.
Wang S; Placzek WJ; Stebbins JL; Mitra S; Noberini R; Koolpe M; Zhang Z; Dahl R; Pasquale EB; Pellecchia M
J Med Chem; 2012 Mar; 55(5):2427-36. PubMed ID: 22329578
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of paclitaxel to EphA2-expressing cancer cells.
Wang S; Noberini R; Stebbins JL; Das S; Zhang Z; Wu B; Mitra S; Billet S; Fernandez A; Bhowmick NA; Kitada S; Pasquale EB; Fisher PB; Pellecchia M
Clin Cancer Res; 2013 Jan; 19(1):128-37. PubMed ID: 23155185
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.
Barile E; Wang S; Das SK; Noberini R; Dahl R; Stebbins JL; Pasquale EB; Fisher PB; Pellecchia M
ChemMedChem; 2014 Jul; 9(7):1403-12. PubMed ID: 24677792
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy.
Guo P; Song S; Li Z; Tian Y; Zheng J; Yang X; Pan W
Int J Pharm; 2015; 486(1-2):356-66. PubMed ID: 25840274
[TBL] [Abstract][Full Text] [Related]
5. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer.
Zhao H; Wang JC; Sun QS; Luo CL; Zhang Q
J Drug Target; 2009 Jan; 17(1):10-8. PubMed ID: 19016068
[TBL] [Abstract][Full Text] [Related]
6. MMAE Delivery Using the
Bennett G; Brown A; Mudd G; Huxley P; Van Rietschoten K; Pavan S; Chen L; Watcham S; Lahdenranta J; Keen N
Mol Cancer Ther; 2020 Jul; 19(7):1385-1394. PubMed ID: 32398269
[TBL] [Abstract][Full Text] [Related]
7. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.
Zhang X; Chen J; Kang Y; Hong S; Zheng Y; Sun H; Xu C
Int J Pharm; 2013 Sep; 453(2):498-505. PubMed ID: 23811008
[TBL] [Abstract][Full Text] [Related]
8. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
9. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
Shen H; Rodriguez-Aguayo C; Xu R; Gonzalez-Villasana V; Mai J; Huang Y; Zhang G; Guo X; Bai L; Qin G; Deng X; Li Q; Erm DR; Aslan B; Liu X; Sakamoto J; Chavez-Reyes A; Han HD; Sood AK; Ferrari M; Lopez-Berestein G
Clin Cancer Res; 2013 Apr; 19(7):1806-15. PubMed ID: 23386691
[TBL] [Abstract][Full Text] [Related]
10. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.
Lee JW; Stone RL; Lee SJ; Nam EJ; Roh JW; Nick AM; Han HD; Shahzad MM; Kim HS; Mangala LS; Jennings NB; Mao S; Gooya J; Jackson D; Coleman RL; Sood AK
Clin Cancer Res; 2010 May; 16(9):2562-70. PubMed ID: 20388851
[TBL] [Abstract][Full Text] [Related]
11. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeting by conjugation of DHA to paclitaxel.
Bradley MO; Swindell CS; Anthony FH; Witman PA; Devanesan P; Webb NL; Baker SD; Wolff AC; Donehower RC
J Control Release; 2001 Jul; 74(1-3):233-6. PubMed ID: 11489499
[TBL] [Abstract][Full Text] [Related]
13. Synergistic dual-targeting hydrogel improves targeting and anticancer effect of Taxol in vitro and in vivo.
Shu C; Li R; Yin Y; Yin D; Gu Y; Ding L; Zhong W
Chem Commun (Camb); 2014 Dec; 50(97):15423-6. PubMed ID: 25349928
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylserine targeting peptide-functionalized pH sensitive mixed micelles for enhanced anti-tumor drug delivery.
Guan S; Zhang Q; Bao J; Duan T; Hu R; Czech T; Tang J
Eur J Pharm Biopharm; 2020 Feb; 147():87-101. PubMed ID: 31899369
[TBL] [Abstract][Full Text] [Related]
15. Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells.
Wu B; Wang S; De SK; Barile E; Quinn BA; Zharkikh I; Purves A; Stebbins JL; Oshima RG; Fisher PB; Pellecchia M
Chem Biol; 2015 Jul; 22(7):876-887. PubMed ID: 26165155
[TBL] [Abstract][Full Text] [Related]
16. Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors.
Passarella RJ; Spratt DE; van der Ende AE; Phillips JG; Wu H; Sathiyakumar V; Zhou L; Hallahan DE; Harth E; Diaz R
Cancer Res; 2010 Jun; 70(11):4550-9. PubMed ID: 20484031
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
[TBL] [Abstract][Full Text] [Related]
18. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
19. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.
Shan L; Zhuo X; Zhang F; Dai Y; Zhu G; Yung BC; Fan W; Zhai K; Jacobson O; Kiesewetter DO; Ma Y; Gao G; Chen X
Theranostics; 2018; 8(7):2018-2030. PubMed ID: 29556370
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship analysis of peptides targeting the EphA2 receptor.
Mitra S; Duggineni S; Koolpe M; Zhu X; Huang Z; Pasquale EB
Biochemistry; 2010 Aug; 49(31):6687-95. PubMed ID: 20677833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]